Drug intelligence / Profile preview

UI-059

Development stage: Phase 1
Lead developer: Korea United Pharm
Modality: Small Molecules
Administration: Oral

Overview

UI-059 is an investigational small molecule drug under clinical development by Korea United Pharm for the treatment of gastroesophageal reflux disease (GERD), including reflux esophagitis. It is currently in Phase 1 clinical trials. The specific mechanism of action has not been disclosed, and no FDA designation or approval has been granted as of now. The drug is administered orally, typically as a tablet formulation.

Beyond the preview

Go deeper on UI-059.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on UI-059.

Explore the full profile